Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aldoxystarch capsules to reduce uremic toxins in peritoneal dialysis patients
ChiCTR2400086908Phase 4Not yet recruiting
- Sponsor
- Gaozhou People's Hospital
- Start
- Jul 2024
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Injectable Hydrogels → Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of aldoxystarch in chronic kidney disease (CKD), end-stage kidney disease (ESKD) and uremia, sponsored by Gaozhou People's Hospital. Primary endpoints: Serum blood urea nitrogen (BUN) and Serum creatinine. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
aldoxystarch
03
Conditions
chronic kidney disease (CKD)end-stage kidney disease (ESKD)uremia
Beyond the preview
Go deeper on ChiCTR2400086908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086908.